New Drugs for the Primary Care Provider: What You Need to Know
|
|
- Madeleine Lambert
- 8 years ago
- Views:
Transcription
1 New Drugs for the Primary Care Provider: What You Need to Know Faculty Financial Disclosure Gerald W. Smetana, MD, has no financial relationships to disclose. Gerald W. Smetana, MD Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical School Objectives Learn which recently approved drugs will have the largest impact on primary care practice Understand the efficacy, side effects, and cost of important novel drugs in primary care practice Learn the role of recently approved medications and their place among existing therapies Important New Drugs for 2014: What We Need to Know Relevant for PCP Novel Drugs No Me Too Drugs FDA New Drug Approvals in 2013: Few Potentially Novel Drugs for Primary Care 2014: Most New Drugs Do Not Meet These Criteria Me Too Drugs, 9 Novel Drugs: 2 Biologicals, 9 Subspecialty Meds, 15 1
2 Three Novel Drugs for Primary Care Practice Historical Perspective Dalcetrapib for the Rx of low HDL cholesterol levels Rivaroxaban for treatment of DVT/PE Canagliflozin for the treatment of type 2 diabetes Man has an inborn craving for medicine The desire to take medicine is one feature which distinguishes man, the animal, from his fellow creatures Even in minor ailments, which would yield to dieting or to simple home remedies, the doctor s visit is not thought to be complete without the prescription. William Osler 1895 Mr. Hartmann Dalcetrapib for Low HDL Levels 66 yo man with CAD and diabetes LDL 86 on atorvastatin HDL 30 Will medication to increase my HDL decrease my risk of MI? The HDL Hypothesis HDL cholesterol is inversely related to cardiovascular risk Drug treatment to raise HDL cholesterol to date has not improved CV outcomes The key question: Is HDL an etiologic factor in CV risk or merely a marker for risk? Theory Behind CETP Inhibition CETP is cholesterol ester transfer protein Cohort of individuals in Japan with defective CETP have high HDL CETP promotes transfer of cholesterol esters from HDL to other proteins Component of reverse cholesterol transport of HDL back to liver for excretion Blocking CETP could raise HDL levels First CETP inhibitor studied was torcetrapib 2
3 ILLUMINATE Mechanism of Torcetrapib Toxicity:? Off Target Effect ILLUMINATE Trial: Torcetrapib Increases: CV Events, CV Mortality, and Noncardiac Mortality Torcetrapib added to atorvastatin increased HDL by 72% Increased cardiac death Doubled rates of noncardiac death Increased systolic bp by 5.4 mm Hg Decreased K+ levels Proposed aldosterone mechanism Independent from CETP inhibition? NEJM 2007;357:2109 Anacetrapib and Dalcetrapib Were Designed to Avoid Off Target Effects Do they reduce cardiovascular risk? Status of CETP Inhibition Through December Torcetrapib increases CV mortality 2. Anacetrapib and dalcetrapib have no off target effects but effect on CV risk unknown RCT: Effect of Dalcetrapib in Patients with Recent ACS N=15,871 Patients hospitalized with ACS or MI Medical Rx +/- PCI All patients receive Rx for LDL when indicated (98% statin use) 4-12 weeks after event, randomly assigned to dalcetrapib 600 mg qd vs. placebo Composite primary CV endpoint at 3 years Dalcetrapib Increases HDL by % LDL Unchanged (mean 76 mg/dl) HDL Cholesterol mg/dl 36% P < NEJM 2012;367:2089 3
4 Key Points Implications for Practice CETP inhibition raises HDL levels by > % Off target effect may explain increased mortality with torcetrapib Dalcetrapib has no off target effects but does not reduce CV risk Anacetrapib does not increased blood pressure but no outcome data yet Proxy outcomes do not predict clinical events Great caution needed CETP inhibition is attractive in theory but no CV benefit proven This is second trial to show harm or no benefit from CETP inhibition Suggests that low HDL may be a marker for CV risk rather than etiologic REVEAL trial of the impact of anacetrapib on CV risk is still ongoing Advise for Mr. Hartmann Continue a statin with goal LDL < 100 Stay with the tried and true Don t hold your breath for new meds for HDL Smile Rivaroxaban to Treat DVT and Pulmonary Embolus Ms. Virchow 28-year-old woman Recent air travel from NRT to LAX Developed LE DVT after the flight LENI s positive Doesn t want to hassle with warfarin How about rivaroxaban? Why Revisit Rivaroxaban? FDA approved July 2011 for VTE prophylaxis after orthopedic surgery Approved November 2011 for stroke prevention in AF New indication for the Rx of DVT and PE 4
5 Anticoagulation: Challenges with Standard Treatment LMWH Requires daily injection Expensive Warfarin Narrow therapeutic range Requires frequent monitoring Major bleeding complications > 3% per year Among top 10 FDA adverse event reports History of Anticoagulants s Heparin Warfarin Fondaparinux Dicumarol Enoxaparin LMWH s Dabigatran Rivaroxaban Desirable Attributes for the Ideal Anticoagulant Oral administration Predictable anticoagulant response No monitoring Rapid onset of action Rapid reversibility Safe antidote No major side effects Targets for Novel Anticoagulants Antithrombin activation Idraparinux (once weekly derivative of fondaparinux Direct thrombin (factor IIa) inhibitors Ximelagatran (withdrawn due to liver toxicity) Dabigatran Factor Xa inhibitors Apixaban Rivaroxaban There is a Reason Why We Didn t Become Hematologists Rivaroxaban Inhibits Factor Xa X VIIa VIIIa Xa IXa Extrinsic Pathway Intrinsic Pathway Va Rivaroxaban Apixaban Prothrombin (II) Fibrinogen Thrombin (IIa) Dabigatran Fibrin 5
6 Rivaroxaban: Pharmacology Brief Summary of VTE Prophylaxis Data: Rivaroxaban is Superior to Enoxaparin and Has Comparable Bleeding Rates Rapid onset after PO dose Half life of 5-9 hours Once daily dosing Predictable anticoagulant response No monitoring required Surgery N Composite Events % RRR RECORD 1 THA vs % RECORD 2 THA vs % RECORD 3 TKA vs % RECORD 4 TKA vs % Lancet 2008;372:6 NOAC: Indirect Comparisons for Stroke Prevention in AF Apixaban Marginally Favored Event %/year Stroke plus major emboli Rivaroxaban Rocket AF Dabigatran RELY Apixaban ARISTOTLE 1.7/ / /1.60 Stroke 2.6/ / /1.5 Mortality 1.9/ / /3.9 Major 3.6/ / /3.1 bleeding CNS bleeding 0.5/ / /0.5 DVT and Pulmonary Embolus Are Morbid Events 300,000 to 600,00 cases / year in U.S % will die within one month of diagnosis 1/3 of patients will have recurrence within 10 years ½ of patients with DVT develop postphlebitic syndrome Outcomes for Rx of DVT/PE for 6 Months of Standard Therapy with LMWH and Warfarin EINSTEIN DVT Trial of Rivaroxaban vs. Standard Rx DVT PE Mortality % % Major bleeding % N = 3449 Proximal DVT No PE GFR > 30 ml/min Exclusions Liver disease Active bleeding Bp > 180/110 Pregnancy Ann Intern Med 2010;578:589 NEJM 2010;363:2499 6
7 EINSTEIN Acute DVT Study: Random Rx Assignments Rivaroxaban 15 mg bid x 3 weeks, then 20 mg qd 3449 patients Enoxaparin 10 mg/kg bid until INR > 2 Primary Endpoint = Recurrent Symptomatic VTE Acute Rx: Rivaroxaban was Non- Inferior for at 6 and 12 Months Rx for 3, 6, or 12 months Warfarin to INR 2-3. Rx for 3, 6, or 12 months Continued Rx: Comparison of Rivaroxaban to Placebo Safety Outcomes in Acute DVT Study: No Significant Differences Compared to Standard Rx Re-randomized to rivaroxaban 20 qd or placebo for an additional 6 or 12 months after completing acute Rx Event Rivaroxaban % Enoxaparin / Warfarin % Major bleeding Fatal bleeding < Non-major bleeding Fatal PE Study d/c Indirect Comparisons to Other Novel Anticoagulants for Rx DVT/PE Indirect Comparisons to Other Novel Anticoagulants for Rx DVT/PE Rivaroxaban Dabigatran Apixaban Study EINSTEIN-DVT RE-COVER AMPLIFY # subjects Primary outcome Outcome vs. standard Rx 2.1% vs. 3.0% 2.4% vs. 2.1% 2.3% vs. 2.7% Major bleeding 0.8% vs. 1.2% 1.6% vs. 1.9% 0.6% vs. 1.8%* Rivaroxaban Dabigatran Apixaban Study EINSTEIN-DVT RE-COVER AMPLIFY # subjects Primary outcome Outcome vs. standard Rx 2.1% vs. 3.0% 2.4% vs. 2.1% 2.3% vs. 2.7% Major bleeding 0.8% vs. 1.2% 1.6% vs. 1.9% 0.6% vs. 1.8%* Curr Cardiol Rep 2014;16:463 Outcomes comparable. Apixaban has marginally less bleeding Curr Cardiol Rep 2014;16:463 Outcomes comparable. Apixaban has marginally less bleeding 7
8 Indirect Comparisons to Other Novel Anticoagulants for Rx DVT/PE Other Considerations Rivaroxaban Dabigatran Apixaban Study EINSTEIN-DVT RE-COVER AMPLIFY # subjects Primary outcome Outcome vs. standard Rx 2.1% vs. 3.0% 2.4% vs. 2.1% 2.3% vs. 2.7% Major bleeding 0.8% vs. 1.2% 1.6% vs. 1.9% 0.6% vs. 1.8%* Outcomes comparable. Apixaban has marginally less bleeding Drug interactions with CYP3A4 inhibitors Must be taken with food Contraindicated during pregnancy (C) Dose adjustment for moderate CKD Must instruct patients to not miss any doses No specific antidote for reversal Approach to bridging uncertain Curr Cardiol Rep 2014;16:463 FDA Approved Indications: Only Rivaroxaban Approved for All 3 Indications Monthly Cost of Outpatient Anticoagulation Dabigatran Apixaban Rivaroxaban Stroke prevention in AF Stroke Prevention in AF Stroke Prevention in AF Postoperative VTE Prophylaxis Rx of DVT and PE Item Cost Rivaroxaban 20 mg qd $295 Dabigatran 150 mg bid $323 Apixaban 5 mg bid $292 Warfarin 5 mg qd $15 INR measurement q 2 weeks $160 $80 x 2 Phlebotomy charge = $15 x 2 $30 Total cost of warfarin $205 plus? Rx Price Quotes.com Feb Rivaroxaban: Key Points Single daily oral dose Non-inferior to warfarin in preventing recurrent VTE Bleeding rates comparable to standard therapy with LMWH and heparin No monitoring required No dietary restrictions No antidote if emergency surgery or major bleeding occurs An appropriate alternative to standard therapy What to Advise Ms. Virchow? LMWH followed by warfarin for at least 3-6 months is standard Rx Rivaroxaban is an acceptable alternative in order to avoid monitoring 8
9 Mr. Sugarman Canagliflozin for Treatment of Type 2 Diabetes 15-year history of type 2 diabetes PMHx hypertension, obesity A1c 8.5% on metformin alone What about adding this new medication canagliflozin? Is this better than adding glyburide? FDA approval May 29, 2013 Percentage with Diabetes Number and Percentage of U.S. Population with Diagnosed Diabetes Percentage with Diabetes Number with Diabetes Number with Diabetes (Millions) Age adjusted Percentage of U.S. Adults with Obesity or Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) O B ES I T Y No Data <14.0% % % % >26.0% Diabetes D IA B ET Year CDC s Division of Diabetes Translation. National Diabetes Surveillance System available at 0 E S No Data <4.5% % % % >9.0% CDC s Division of Diabetes Translation. National Diabetes Surveillance System available at History of Diabetes Medications Canagliflozin is a Novel SGL2 Inhibitor 1921 Insulin 1942 Sulfonylureas 1994 Metformin 1999 Rosiglitazone 2005 Exenatide 2006 Sitagliptin 2013 Canagliflozin Sodium-glucose co-transporter 2 = SGL2 Selective membrane protein expressed in kidney Transports glucose from proximal tubular lumen to epithelial cells Canagliflozin blocks SGL2, prevents glucose reabsorption, and causes glucosuria Decreases blood glucose 9
10 Effect of Canagliflozin Monotherapy in Type 2 Diabetes N=584 A1c 7-10% at baseline Randomly assigned to: Canagliflozin 100 mg qd Canagliflozin 300 mg qd Placebo 26 week follow up Primary endpoint = change in A1c Diabetes Obes Metab. 2013;15:372 Most Patients Achieved 7% A1c Goal at 300 mg qd Dose Placebo Cana 100 mg Cana 300 mg A1c < 7% A1c < 6.5% P < 0.01 P > 0.05 Adverse Effects Among Pooled Studies Adverse Effects Among Pooled Studies Event Placebo Canagliflozin 100 mg qd % Canagliflozin 300 mg qd % Any Rx discontinuation Constipation UTI Polyuria Balanitis Vaginal candidiasis Orthostasis < Rash / urticaria NA < 2 < 2 Event Placebo Canagliflozin 100 mg qd % Canagliflozin 300 mg qd % Any Rx discontinuation Constipation UTI Polyuria Balanitis Vaginal candidiasis Orthostasis < Rash / urticaria NA < 2 < 2 Mean Change in A1c and Weight for Approved Drugs for Diabetes Cost: AWP for Selected Agents Agent A1c (%) Δ Weight (kg) Insulin DCCT conventional Insulin DCCT intensive Sulfonylureas to Metformin to -0.8 Thiazolidinediones to +3.5 GLP-1 agonists 0.4 to to -2.8 DPP-4 inhibitors to -1.0 Canagliflozin to 3.3 Oral Monthly Cost (USD) Glipizide 10 mg qd 4 Metformin 1500 mg qd 30 Pioglitazone 15 mg qd 45 Sitagliptin 100 mg qd 246 Canagliflozin 100 mg qd 263 Injectable Exenatide 10 mcg bid 350 Insulin Glargine 2 pens 90 Medical Letter May
11 What To Add After Metformin? Advantages Disadvantages Sulfonylurea Most A1c reduction Hypoglycemia Glitazones No hypoglycemia Weight gain Fluid retention GLP-1 Agonists DPP-4 Inhibitors Insulin Canagliflozin No hypoglycemia Weight loss No hypoglycemia Effective Weight loss BP reduction Injections Nausea Less effective Long term side effects? Injections Hypoglycemia Yeast infections UTIs Other Considerations Less A1c reduction (0.6%) for patients with CKD Reduces systolic bp by 4-8 mm Hg LDL increase 8 mg/dl Small increase in serum PO 4 and Mg Rarely may cause hyperkalemia, hypotension Does not cause hypoglycemia in monotherapy Small reduction in BMD Dapagliflozin, available in Europe, denied by FDA due to possible risk of breast and bladder cancer Key Points Dose 100 to 300 mg qd Adjust for CKD; contraindicated for GFR < 45 A1c reduction comparable to other agents Glucosuria causes weight loss More weight loss than any other Rx May cause polyuria and orthostasis Yeast and urinary tract infections? Potential for long term CA risk Very expensive Summary Dalcetrapib raises HDL without affecting blood pressure, but does not reduce CV risk Rivaroxaban is non-inferior to warfarin for the treatment of DVT/PE and requires no monitoring Canagliflozin reduces A1c and weight; though long term safety is unknown A Final Thought For some patients, though conscious that their condition is perilous, recover their health simply through contentment with the goodness of their physician. Hippocrates ( BC) 11
New Drugs for the Primary Care Provider: What You Need to Know
Presenter Disclosure Information 11:05 11:45am New Drugs for PCP: What You Need to Know SPEAKER Gerald Smetana, MD The following relationships exist related to this presentation: Gerald W. Smetana, MD:
More informationNew Drugs for PCP: What You Need to Know
New Drugs for PCP: What You Need to Know Learning Objectives 1. List the recently approved drugs will have the largest impact on primary care practice 2. Discuss the efficacy, side effects, and cost of
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationXarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason
Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationGruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More information3/3/2015. Patrick Cobb, MD, FACP March 2015
Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationStepping Beyond Warfarin:
Stepping Beyond Warfarin: Working with Novel Oral Anticoagulants (NOACs) in Clinical Practice USAFP 2015 CPT Tyler R Reese, MD US Army, Medical Corps Tripler Army Medical Center Disclosures: Neither I,
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationEINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012
EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationNew Anticoagulation Agents
New Anticoagulation Agents Use of New and Older Therapeutic Agents in the Treatment Regimen Michelle Geddes Case 1 40 year old woman with idiopathic proximal DVT. Previous heparin allergy (wheals, hives)
More informationConserva)ve Treatment of PE/ DVT
Conserva)ve Treatment of PE/ DVT Amir Kaki, MD FACC FSCAI Asst Prof of Medicine Wayne St SOM Medical Director Cardiac Catheteriza)on Lab Heart Hospital DMC Detroit, MI Incidence Acute pulmonary embolism
More informationHome treatment of VTE
Home treatment of VTE Prof. Adel El-Etriby Ain-Shams University Venous Thromboembolism (VTE): The DVT and PE Continuum Migration Embolus Thrombus VTE refers to a continuum of disease that begins with DVT
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationWill Next Generation Oral Anticoagulants Replace Warfarin as Mainstay Therapy?
Brochure More information from http://www.researchandmarkets.com/reports/1869007/ Will Next Generation Oral Anticoagulants Replace Warfarin as Mainstay Therapy? Description: Will Next Generation Oral Anticoagulants
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationAdvanced Issues in Peri-Operative VTE Prevention
Advanced Issues in Peri-Operative VTE Prevention Michael-Anthony (M-A) Williams, M.D. Consultant Physician Centura Medical Consultants September 27th, 2012 Main Topics 1. The perils of the early mover-
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationPulmonary Embolism Treatment Update
UC SF Pulmonary Embolism Treatment Update Jeffrey Tabas, MD Professor UCSF School of Medicine Emergency Department San Francisco General Hospital sf g h Disclosure No Financial Relationships to Disclose
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More informationNewer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationEfficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
More informationThe New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences
The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences Center September 25, 2015 Question: With which of the
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationComparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationAcute behandeling van longembolie. Peter Verhamme. Bloedings- en Vaatziekten UZ Leuven. Research support and/or honoraria:
Acute behandeling van longembolie Peter Verhamme Bloedings- en Vaatziekten UZ Leuven Disclosures Research support and/or honoraria: Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Pfizer, BMS, Sanofi, Leo-pharma
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationNew Anticoagulants and GI bleeding
New Anticoagulants and GI bleeding DR DANNY MYERS MD FRCP(C) CLINICAL ASSISTANT PROFESSOR OF MEDICINE, UBC Conflicts of Interest None I am unbiased in the use of NOAC s vs Warfarin based on risk benefit
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationrivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC
rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationProgram Objectives. Why Use Anticoagulants? 6/5/2014
Larry Reis RPh CGP FASCP Prepared June 2014 for NADONA REIS RXCARE CONSULTING Reisrxcare@comcast.net 1 Program Objectives Discuss complications of current anticoagulant Rx Identify risks of using anticoagulants
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationThe Anticoagulated Patient A Hematologist s Perspective
The Anticoagulated Patient A Hematologist s Perspective Deborah M. Siegal MD MSc FRCPC Clinical Scholar Division of Hematology and Thromboembolism Thrombosis Canada Research Fellow McMaster University
More informationRivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationAnticoagulants. Denver Health April 12, 2011
New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis
More information9/5/14. Objectives. Atrial Fibrillation (AF)
Novel Anticoagulation for Prevention of Stroke in Patients with Atrial Fibrillation Objectives 1. Review current evidence on use of warfarin in individuals with atrial fibrillation 2. Compare the three
More information